# A Phase I Study of XJ101 in Chinese Healthy Subjects

> **NCT06014736** · PHASE1 · UNKNOWN · sponsor: **Starmab biologics（Shanghai）Co,.ltd** · enrollment: 38 (actual)

## Conditions studied

- Staphylococcus Aureus Bloodstream Infection

## Interventions

- **DRUG:** XJ101 for Injection
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06014736
- **Lead sponsor:** Starmab biologics（Shanghai）Co,.ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08-15
- **Primary completion:** 2024-03-26
- **Final completion:** 2024-09-01
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2024-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06014736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06014736, "A Phase I Study of XJ101 in Chinese Healthy Subjects". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT06014736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*